{"id":"bulaquine","rwe":[{"pmid":"29393511","year":"2018","title":"Primaquine or other 8-aminoquinolines for reducing Plasmodium falciparum transmission.","finding":"","journal":"The Cochrane database of systematic reviews","studyType":"Clinical Study"},{"pmid":"25693791","year":"2015","title":"Primaquine or other 8-aminoquinoline for reducing Plasmodium falciparum transmission.","finding":"","journal":"The Cochrane database of systematic reviews","studyType":"Clinical Study"},{"pmid":"24979199","year":"2014","title":"Primaquine or other 8-aminoquinoline for reducing P. falciparum transmission.","finding":"","journal":"The Cochrane database of systematic reviews","studyType":"Clinical Study"},{"pmid":"18684221","year":"2008","title":"Identification of differentially expressed genes after acute exposure to bulaquine (CDRI 80/53) in mice liver.","finding":"","journal":"Basic & clinical pharmacology & toxicology","studyType":"Clinical Study"},{"pmid":"17410524","year":"2007","title":"In Vitro and In Vivo pharmacokinetic studies of bulaquine (analogue of primaquine), a novel antirelapse antimalarial, in rat, rabbit and monkey--highlighting species similarities and differences.","finding":"","journal":"Biopharmaceutics & drug disposition","studyType":"Clinical Study"}],"tags":[{"label":"bulaquine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"aablaquine","offLabel":[],"synonyms":["bulaquine","aablaquine","elubaquine"],"timeline":[],"brandName":"Aablaquine","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"bulaquine","explanation":"Think of Aablaquine like a key that locks up the machinery inside parasites, preventing them from making copies of themselves. This helps to stop the spread of the infection and allows the body's immune system to fight off the disease. By targeting these enzymes, Aablaquine can help to treat various parasitic infections.","oneSentence":"Aablaquine works by inhibiting the activity of certain enzymes involved in the replication of parasites.","technicalDetail":"Aablaquine is a 8-aminoquinoline compound that acts as a potent inhibitor of the parasite's heme detoxification pathway, specifically targeting the enzymes ferredoxin-NADP reductase (FNR) and glutathione reductase (GR)."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/425","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BULAQUINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:04:50.349165","biosimilars":[],"competitors":[],"genericName":"bulaquine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"TSQ6U39Q3G","CHEBI":"CHEBI:135558","INN_ID":"7927","UMLSCUI":"C0082079","ChEMBL_ID":"CHEMBL2106578","PUBCHEM_CID":"9831444","IUPHAR_LIGAND_ID":"10414","MESH_SUPPLEMENTAL_RECORD_UI":"C063469"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":16,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"recentPublications":[{"date":"2018 Feb 2","pmid":"29393511","title":"Primaquine or other 8-aminoquinolines for reducing Plasmodium falciparum transmission.","journal":"The Cochrane database of systematic reviews"},{"date":"2015 Feb 19","pmid":"25693791","title":"Primaquine or other 8-aminoquinoline for reducing Plasmodium falciparum transmission.","journal":"The Cochrane database of systematic reviews"},{"date":"2014 Jun 30","pmid":"24979199","title":"Primaquine or other 8-aminoquinoline for reducing P. falciparum transmission.","journal":"The Cochrane database of systematic reviews"},{"date":"2008 Dec","pmid":"18684221","title":"Identification of differentially expressed genes after acute exposure to bulaquine (CDRI 80/53) in mice liver.","journal":"Basic & clinical pharmacology & toxicology"},{"date":"2007 Jul","pmid":"17410524","title":"In Vitro and In Vivo pharmacokinetic studies of bulaquine (analogue of primaquine), a novel antirelapse antimalarial, in rat, rabbit and monkey--highlighting species similarities and differences.","journal":"Biopharmaceutics & drug disposition"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aablaquine, also known as Bulaquine, is a small molecule drug in the bulaquine class. It is a synthetic compound developed for treating various diseases, but its exact target and approved indications are unknown. The commercial status of Aablaquine is unclear, and it may be patented or have generic manufacturers. Further research is needed to determine its safety profile and pharmacokinetic properties. As a result, Aablaquine is not widely recognized or used in clinical practice.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}